Multicenter case–control study protocol of pneumonia etiology in children: Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL network) by Valentina Sanchez Picot et al.
STUDY PROTOCOL Open Access
Multicenter case–control study protocol of
pneumonia etiology in children: Global Approach
to Biological Research, Infectious diseases and
Epidemics in Low-income countries
(GABRIEL network)
Valentina Sanchez Picot1†, Thomas Bénet2,3†, Melina Messaoudi1, Jean-Noël Telles1, Monidarin Chou4,
Tekchheng Eap5, Jianwei Wang6, Kunling Shen7, Jean-William Pape8, Vanessa Rouzier8, Shally Awasthi9,
Nitin Pandey9, Ashish Bavdekar10, Sonali Sanghvi10, Annick Robinson11, Bénédicte Contamin12,
Jonathan Hoffmann12, Maryam Sylla13, Souleymane Diallo14, Pagbajabyn Nymadawa15,
Budragchaagiin Dash-Yandag16, Graciela Russomando17, Wilma Basualdo18, Marilda M Siqueira19, Patricia Barreto19,
Florence Komurian-Pradel1, Guy Vernet1, Hubert Endtz1, Philippe Vanhems2,3, Gláucia Paranhos-Baccalà1*
and on behalf of the pneumonia GABRIEL network
Abstract
Background: Data on the etiologies of pneumonia among children are inadequate, especially in developing countries.
The principal objective is to undertake a multicenter incident case–control study of <5-year-old children hospitalized
with pneumonia in developing and emerging countries, aiming to identify the causative agents involved in pneumonia
while assessing individual and microbial factors associated with the risk of severe pneumonia.
Methods/design: A multicenter case–control study, based on the GABRIEL network, is ongoing. Ten study sites are
located in 9 countries over 3 continents: Brazil, Cambodia, China, Haiti, India, Madagascar, Mali, Mongolia, and Paraguay.
At least 1,000 incident cases and 1,000 controls will be enrolled and matched for age and date. Cases are hospitalized
children <5 years with radiologically confirmed pneumonia, and the controls are children without any features
suggestive of pneumonia. Respiratory specimens are collected from all enrolled subjects to identify 19 viruses and 5
bacteria. Whole blood from pneumonia cases is being tested for 3 major bacteria. S. pneumoniae-positive specimens
are serotyped. Urine samples from cases only are tested for detection of antimicrobial activity. The association between
procalcitonin, C-reactive protein and pathogens is being evaluated. A discovery platform will enable pathogen
identification in undiagnosed samples.
Discussion: This multicenter study will provide descriptive results for better understanding of pathogens responsible
for pneumonia among children in developing countries. The identification of determinants related to microorganisms
associated with pneumonia and its severity should facilitate treatment and prevention.
Keywords: Pneumonia, Children, Case–control, Etiology, Developing and emerging countries
* Correspondence: glaucia.baccala@fondation-merieux.org
†Equal contributors
1Emerging Pathogens Laboratory – Fondation Mérieux, Centre International
de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de
Lyon, UCBL1, 21, Avenue Tony Garnier, Lyon 69007, France
Full list of author information is available at the end of the article
© 2014 Picot et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Picot et al. BMC Infectious Diseases 2014, 14:635
http://www.biomedcentral.com/1471-2334/14/635
Background
With more than 120,000 million episodes occurring
worldwide every year [1], pneumonia is the leading cause
of child mortality from infectious diseases, accounting for
an estimated 1 million deaths annually, and mainly afflict-
ing children in developing countries according to Global
Health Observatory [2]. Mortality attributed to pneumonia
has decreased since 2000, but remains a major public
health concern [3]. Improvements in medical care and
the implementation of vaccination policies may have
contributed to the decline in mortality [1]. However,
data on the etiology and epidemiology of pneumonia in
developing countries are still insufficient. Indeed, large
studies that investigated the etiology of pneumonia in chil-
dren were undertaken more than 20 years ago [4]. During
this time, several epidemiological factors, such as human
immunodeficiency virus (HIV) pandemic, Streptococcus
pneumoniae and Haemophilus influenzae vaccine imple-
mentation, might have modified the global distribution of
causative pathogens [1,5,6]. Moreover, the development of
molecular techniques in the last few decades has led to the
detection of numerous pathogens, mainly viruses [7,8]
(Figure 1).
The etiology of pneumonia could be either bacterial or
viral.[9] The main known causative pathogens are Strepto-
coccus pneumoniae [5,10]. Haemophilus influenzae [6],
and respiratory syncitial virus (RSV) [11]. Interactions
between viruses, bacteria and host are complex and re-
main poorly explored [12,13]. In outbreak situations, data
on the spatial and temporal distribution of etiological
agents are key to identification and control. Several pre-
dictors of pneumonia or severe pneumonia have been
found [14,15]. However, the association with pneumonia
etiology has not been fully investigated [15]. Indeed, the
identification of factors strongly linked with complications
or death could help in the development of appropriate
therapeutic management strategies for these patients.
The purpose of the present work is to summarize the
protocol of the multicenter incident case–control study of
pneumonia in children less than 5 years of age, aiming to
identify the etiological agents and related determinants in-
volved in pneumonia. The countries participating in this
study account for a significant part of the pneumonia bur-
den in children worldwide. For example, India recorded
around 35 million new cases of pneumonia in 2010, with
the highest numbers of deaths in the world (390,000),
while China has 6 million cases and ranks fifth, with about
43,000 deaths annually [16]. Although pneumonia is still a
major cause of mortality in other countries, observational
data on pneumonia etiology are very sparse [16]. In
Madagascar, for example, apart from earlier studies on in-
fluenza A and B viruses [17], to our knowledge, no other
data are available on respiratory viruses and their trans-























Figure 1 Map of the world showing participating sites of the multicenter case–control study of pneumonia etiology in children.




The study’s primary objectives are to identify the causative
agents involved in the onset of pneumonia in children and
to assess individual and microbial factors associated with
the risk of pneumonia, including severe pneumonia. Its sec-
ondary objectives are: 1) to examine the value of C-reactive
protein (CRP) and procalcitonin (PCT) in predicting the se-
verity of pneumonia or infection by particular pathogens, 2)
to estimate the involvement of etiological agents in pneu-
monia, and 3) to characterize new infectious agents or vari-
ants in pneumonia of unknown etiology.
Study sites and design
This prospective, hospital-based, multicenter case–con-
trol study is being conducted at 10 sites in 9 countries –
Brazil, Cambodia, China, Haiti, India (2 sites: Pune/Vadu
and Lucknow), Madagascar, Mali, Mongolia, Paraguay –
on 3 continents. Enrollment of at least 100 incident cases
and 100 controls during 12 months is planned for each
participating site for a total sample of at least 2,000 sub-
jects. The participating sites are members of the GABRIEL
network of Fondation Mérieux [18]. Table 1 reports the
demographic characteristics and burden of pneumonia in
each participating country. Laboratory data are generated
by local sites after reaching capacity, via technology
transfer and training by the Emerging Pathogens Labora-
tory of Fondation Mérieux (Lyon, France).
Study participants
The study population, comprised of children under 5 years
of age, complies with protocol definitions and inclusion
criteria. Eligible patients are identified by study pediatri-
cians at each participating site. Cases are defined by the
following criteria: 1) Hospitalized patients aged between
2 months and 59 months, 2) Clinical features of pneumo-
nia, as described below, 3) radiological confirmation of
pneumonia on chest X-ray as per WHO guidelines [19],
and 3) Informed consent statement signed by the chil-
dren’s parents or legal guardian. The exclusion criterion
for cases are the following: presence of wheezing at
auscultation, or minors whose parents or legal guardian
declined to sign the informed consent statement.
Controls are defined by the following criteria: 1) Pa-
tients aged between 2 months and 59 months, 2) Hospi-
talized for surgery or in a routine outpatient practice
environment, and 3) Informed consent statement signed
by the children’s parents or legal guardian. Exclusion cri-
teria for the controls are: 1) Any symptom suggestive of
respiratory illness, or 2) Minors whose parents or legal
guardian decline to sign the informed consent statement.
Cases and controls are matched for study site, age
(±1 year) and calendar date of hospital admission
(±1 month).
Definition of pneumonia
Pneumonia cases are defined by the following:
– Cough and/or dyspnea, and
– Tachypnea, as defined by the World Health
Organization (WHO) (in children between 2 and
12 months of age: breathing rate ≥50 cycles per
minute; in children between 12 months and
59 months of age: breathing rate ≥40 cycles per
minute) [20], and
– Absence of wheezing at auscultation, and
– First symptoms appearing within the last
14 days, and
– Radiological confirmation of pneumonia as per
WHO guidelines [19].
Data sources and quality control
Research conduct and management are organized by the
Emerging Pathogens Laboratory of Fondation Mérieux,
primarily for evaluation and monitoring of the ethics,
regulatory, clinical, laboratory and data generation com-
ponents at each participating site. Tasks and responsibil-
ities are based on standard research guidelines, including
standard operating procedures. Data quality is monitored
and evaluated by each site and by the Emerging Pathogens
Laboratory for pooled data analysis. Demographic charac-
teristics, underlying diseases, medical history, clinical
examination at enrollment, radiological findings, vaccina-
tions, and outcome are recorded prospectively for each
patient on a standardized form (Table 2).
Data quality reporting is redacted for each site to en-
sure the conformity of all study data variables, it will de-
tailed enrollment and case definition conformity, errors,
and missing data [21,22]. This process will be applied to
data analysis of each enrolled case and control. Each po-
tential error is discussed, and a final rule applied. The
principal investigator at each site is informed for queries
regarding this quality assessment and is involved in reso-
lution. A tracking system is applied to the process.
Biological samples
Samples are collected in the first 48 hours of the patient
hospitalization. Nasal swabs/aspirates are collected from
all pneumonia cases and controls. This collection pro-
cedure is performed by trained clinical staff, nurses and
the principal investigator. Additional specimens are from
cases only, including urine, whole blood and pleural ef-
fusions (Table 3). Antibiotic substances are detected in
urine samples from all pneumonia cases to detect anti-
biotic usage history. Whole blood is collected and dis-
tributed in Ethylene-diamine-tetra-acetic acid (EDTA)
vials for preservation and in dry tubes for serum speci-
mens. EDTA-whole blood samples allow complete blood
count, blood culture and real-time multiplex polymerase
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Table 1 Description of sites in multicenter case–control study of pneumonia etiology in children


































Urban Rain/Dry 199 (2009) 6.1 (2009) 16 1,497,706 3,079 2010 1999
National Pediatric
Hospital



































India Lucknow Chatrapati Shahuji
Maharaj University





Madagascar Antananarivo Centre Charles
Mérieux
Urban Rain/Dry 22.3 (2012) 81.3 (2010) 62 1,051,407 2,638 2011 2008
Gabriel Toure
Hospital
Mali Bamako Centre Charles
Mérieux
Urban/rural Rain/Dry 14.9 (2012) 50.4 (2010) 176 932,894 7,893 2008 2011
Bayanzurkh District
General Hospital










Paraguay San Lorenzo Research Institute
of Health
Urban/rural Rain/Dry 6.7 (2009) 7.2 (2012) 22 139,661 368 2012 2002
aInternational Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. Vaccine Information Management System (VIMS) Global Vaccine Introduction Report, October
2013. www.jhsph.edu/ivac/vims.html.
bWorld Bank Group: http://povertydata.worldbank.org.
cData from Rudan I, O’Brien KL, Nair H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192
countries. J Glob Health 2013;3:010401.
dPneumococcal conjugate vaccine.
eHaemophilus influenzae type B.



















chain reaction (PCR) assay for the identification of
Staphylococcus aureus, Streptococcus pneumoniae and
Haemophilus influenzae type B. CRP and PCT are mea-
sured quantitatively in serum. Respiratory specimens
(nasal swabs/aspirates and pleural effusions) will permit
to identify viruses and bacteria by real-time multiplex
PCR assay with a panel of 19 viruses and 5 bacteria
(FTD respiratory pathogens 21 PLUS (Fast-track Diagnos-
tic, Luxemburg). The pathogens targeted are: influenza A,
H1N1, influenza B, coronavirus 229E, coronavirus OC43,
coronavirus NL63, coronavirus HKU1, parainfluenza virus
1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza
virus 4, human metapneumoviruses A and B, rhinovirus,
RSVs A and B, adenovirus, enterovirus, parechovirus, boca-
virus), Mycoplasma pneumoniae, Chlamydia pneumoniae,
S. aureus, S. pneumoniae, and H. influenzae type B. S. pneu-
moniae-positive specimens are serotyped with a multiplex
real-time PCR method that detects 29 different serotypes
(1, 3, 4, 5, 6A/B, 7C, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B/
C, 16F, 17F, Sg18C, 19A, 19F, 20, 22F, 23F, 31, 33F, 34, 35B,
35F, 38 and Lyt A). A centralized, blinded PCR respiratory
quality control panel is also provided to all sites to ensure
procedure validation on site before specimens are proc-
essed locally. The control panel is processed every 3 months
at each laboratory site. Each laboratory has to successfully
test the control panels to proceed with the study.
Potential bias
Because the study concerns hospitalized pneumonia cases,
the magnitude of putative selection bias according to dis-
ease severity will be evaluated for cases and controls. Con-
trol charts will detect evolving selection bias over time at
particular sites [21]. Patients’ characteristics and the clin-
ical presentation of pneumonia cases will be described and
compared between sites. Precise evaluation of diagnostic
Table 2 Individual questionnaire among cases and
controls in multicenter case–control study of
pneumonia etiology in children
Category Information
General Hospital Country
Demographic Gender Date of birth
Underlying
diseases
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Acute complications Cause of death
Recovery
Table 3 Laboratory tests in multicenter case–control
study of pneumonia etiology in children
Samples Population Analyses
Nasal swab/aspirate Cases and controls Molecular detection of
viruses and bacteria
S. pneumoniae typing
Pleural effusion Cases (if pleuritis) Molecular detection of
viruses and bacteria
S. pneumoniae typing





Serum Cases C-reactive protein
Procalcitonin
Urine Cases Broad antibiotic detection
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criteria and standardized biological tests with central ana-
lysis should reduce misclassification bias. A flow chart
describing the quality of case enrollment and follow-up is
constructed by site and for pooled populations. Based on
past experiences in multicenter pneumonia studies, par-
ticular attention will be paid to standardization of case
definition [4,23]. Moreover, heterogeneity of the raw data
will be compared between sites. This process will precisely
define the population that is enrolled in the pooled ana-
lysis, according to data validity and population homo-
geneity. Multivariate analysis (described above) will take
the main confounding factors into account.
Study size power calculation
With 100 cases and 100 controls per site, analysis in a
particular site will have 80% power to detect odds ratios
(OR) ≥3 with prevalence of exposure ≥20% for the con-
trols, whatever the prevalence of exposure associated
with a case. With 1,000 cases and 1,000 controls, overall
analysis will have 90% power to detect OR ≥ 2 with
exposure in controls ≥5%, whatever the prevalence of
exposure associated with a case. Therefore, the study
will include at least 2,000 patients; at least 100 cases and
100 controls enrolled at each participating site.
Statistical methods
An anonymous database will be built and analyzed.
Quantitative variables will be described and categorized
according to their distribution in the study population.
The proportion of missing data will be described for all
variables, and the mechanism of missing data will be
researched; a multiple imputation process of missing
data will be implemented, if necessary. Descriptive ana-
lysis will address each covariate for the entire popula-
tion, and stratified by site. If multiple microorganisms
are detected, typology of co-infections will be developed.
Co-infections/colonization will be reported by site,
patients’ characteristics and time.
Patients’ characteristics and microbiological data on
cases and controls will be compared. Mixed effects logis-
tic univariate and multivariate regression modeling will
be applied to assess factors associated with pneumonia
or infection by particular pathogens. These models will
take into account heterogeneity in baseline risk between
sites and countries as well as the nested nature of the
data. Indeed, microbial agents are nested in patients be-
cause they could be infected by several agents; patients
are nested in sites and countries. Other analysis will
focus on factors associated with co-infection, for each
possible pair or trio of microorganisms. Individual and
microbial factors linked with the risk of severe disease or
death will be analyzed by survival models, if applicable.
Sensitivity, specificity and predictive values will be calcu-
lated to research the value of CRP and PCT in predicting
the severity of pneumonia or infection by particular patho-
gens. Complementary methods and stratified analyses will
be deployed, if necessary, to study the distribution of the
causative agents of pneumonia according the underlying
medical condition such as HIV for example.
Ethics and confidentiality
The study protocol, informed consent statement, clinical
research form, any amendments and all other study
documents have been submitted to and approved by the
institutional ethics committee of each site: Brazil (Conselho
Nacional de Saúde, Comissão Nacional de Ética em
Pesquisa, Ministerio da Saúde), China (National Ethics
Committee, Ministry of Health, Cambodia (National Ethics
Commitee for Health Research, Ministry of Health), Haïti
(Comité des Droits Humains des Centres GHESKIO, Comité
National d’Ethique, Ministère de la Santé Publique et de la
Population, and Institutional Review Board of Weill Cornell
Medical College), India Lucknow center (Institutional
Ethics Committee, Chhatrapati Shahuji Maharaj Medical
University, Uttar Pradesh), India Pune (Ethics Commity at
KEM hospital research centre), Madagascar (Comité
d’Ethique, Ministère de la Santé Publique), Mali (Comité
national d’éthique pour la santé et les sciences de la vie),
Mongolia (Ethical committee for medical research), and
Paraguay (Comité de Ética en Investigación del Instituto de
Investigaciones en Ciencias de la Salud de la Universidad
Nacional de Asunción).
Discussion
Multicenter pneumonia study analysis will be reported
for publication in 2015. Individual site analysis, focusing
on particular interests, will also be described and pub-
lished at a later date.
Study analysis will generally focus on the description of
causative pathogens at the onset of pneumonia for the en-
tire population and by country site. Several studies have
already investigated the etiology of pneumonia [24]. How-
ever, they were limited by either unicentric study design
[14], focused on a particular pathogen [25], lacked a con-
trol group [26], or employed diagnosis techniques with
limited sensitivity [24]. Many reports came from high-
income countries, in highly-selected populations, such as
patients with pneumonia requiring intensive care unit stay
[27]. Data are lacking on pneumonia etiology in develop-
ing countries based on worldwide distribution of study
sites. A better understanding of pathogens causing
pneumonia in children should contribute to improved
preventive – through implementation of vaccine policies –
and therapeutic management, ultimately leading to reduced
morbidity and mortality of pneumonia in children. More-
over, CRP combined with PCT has demonstrated value in
predicting pneumonia in adults, but interest in pediatric
populations as not been well demonstrated [28,29].
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Thus, our study should provide new data on the fol-
lowing questions: What are the viral and bacterial etio-
logical agents of pneumonia in children under 5 years
of age in developing and emerging countries? What is
their seasonal distribution? What are the circulating
pneumococcal serotypes? What is the distribution of co-
infections? What is the clinical profile of co-infected
patients? Are CRP and PCT predictive markers of
pneumonia etiology? Which pathogen is presented in
samples without any etiology?
Several study weaknesses should be considered, in-
cluding bias, confounders and statistical power. Firstly,
potential selection bias with different mechanisms of se-
lection between sites might occur. Indeed, a particular
site might include cases according to a definition that
does not exactly conform to standardized case definition,
as with the controls. Another example might be the se-
lection of subjects due to local clinical practices or field
experiences. These different mechanisms of selection
could jeopardize data interpretation, by site and pooled
analysis [30]. Some subjects’ results might be excluded
from the overall analysis. Secondly, external validity
could be questioned by site compared to the country
population to assess representativeness of the study
population, and compared with the world population
for pooled analysis [30]. Thirdly, limited information
might be available on exposures preceding pneumonia
occurrence. Also, some confounding related to nutri-
tion or parental history factors, will be missing at the
individual level. However, the geographical (i.e., rain-
fall, temperature) and socio-cultural (i.e., type of popu-
lation) context as well as study site and local health
care system characteristics will be described [31].
Finally, the quality and distribution of variables will
limit some statistical analyses, with an impact on study
power. Thus, multiple imputations as assumption
checking before modeling will also be a key issue be-
fore running statistical analysis.
The study’s main strength is the prospective collec-
tion of multiple biological samples that should permit
the diagnosis of etiological agents involved in pneu-
monia as well as the importance of colonization by
other microbial agents. Another advantage is the mul-
ticenter study design that will permit the description
of various etiologies of pneumonia in study-related re-
gions of the world [18]. It is noteworthy that the two
most populous countries in the world, which represent
a large burden of pneumonia incidence and mortality
worldwide – China and India – are part of the study
[16]. The results of our multicenter pneumonia study
could be possibly compared with those of other con-
temporary pneumonia investigations. In this regard,
the ongoing Pneumonia Etiology Research for Child
Health (PERCH) study will be particularly informative
[32]. Indeed, study design, case definition, molecular
techniques and biological samples, while not identical,
are not very different between the two multicenter
works [33,34]. PERCH is larger than the present study,
but countries such as India and China are not partici-
pating in it while they are included in our multicenter
pneumonia investigation. Also, comparative analyses
might be considered as a perspective that could offer
new insights into pneumonia etiologies worldwide.
Conclusion
In conclusion, our multicenter pneumonia study will
detail pneumonia etiologies among children in 9 coun-
tries on 3 continents. The results could be helpful not
only in improving individual care but also in formulating
appropriate public health policies [35].
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